| Field | Specification |
|---|---|
| Target | |
| Alternative names | Cytochrome P450 2C19; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; S)-limonene 7-monooxygenase; CYPIIC17; CYPIIC19; Cytochrome P450-11A; Cytochrome P450-254C; Mephenytoin 4-hydroxylase; CYP2C19 |
| UniProt # | |
| Host | |
| Clonality | |
| Isotype | |
| Reactivity | |
| Applications | |
| Immunogen | A synthetic peptide corresponding to a sequence in the middle region of human Cytochrome p450 2C19/CYP2C19. |
| Molecular weight | |
| Purification | |
| Reconstitution | |
| Cellular localization | |
| Concentration | |
| Form | Lyophilized |
| Storage | |
| Catalog no. (Mfr.) | |
| Main SKU |
Product Overview
This rabbit polyclonal antibody targets cytochrome P450 2C19 (gene CYP2C19) in human, mouse and rat samples and is validated for Western blot and IHC. The predicted molecular weight is 55.9 kDa, and the supplier reports an observed band at about 56 kDa.
CYP2C19 is a liver cytochrome P450 enzyme that metabolizes several widely used drugs, including clopidogrel, proton pump inhibitors and some antidepressants, as well as fatty acids. Common genetic variants create poor and rapid metabolizer phenotypes, making CYP2C19 one of the best-known examples in pharmacogenetics.
| Target | Cytochrome P450 2C19 (gene CYP2C19; UniProt P33261, human) |
|---|---|
| Host / Clonality / Isotype | Rabbit / Polyclonal / Rabbit IgG |
| Reactivity | Human, Mouse, Rat |
| Form | Lyophilized |
| Formulation | Per vial: 4 mg trehalose; 0.9 mg NaCl; 0.2 mg Na2HPO4; 0.05 mg NaN3 |
| Calculated MW | 55.9 kDa |
| Observed MW | 56 kDa |
| Storage | As supplied: −20 °C for up to 12 months from receipt. After reconstitution: 4 °C for up to 1 month, or aliquot and keep at −20 °C for up to 6 months. Avoid repeated freeze–thaw cycles. |
Validated Applications
| Western blot | 0.1–0.5 µg/mL |
|---|---|
| IHC (paraffin sections) | 0.5–1 µg/mL |
Samples with a confirmed band (WB): rat liver tissue.
Recommended loading (WB): 20–40 µg of total protein per lane.
Conditions in the example images (WB): 5–20% gradient SDS-PAGE under reducing conditions, 50 µg lysate per lane, transfer to nitrocellulose membrane, blocking in 5% non-fat milk, primary antibody at 0.5 µg/mL overnight at 4 °C, HRP-conjugated secondary antibody at 1:10000, ECL detection.
Samples with confirmed staining (IHC): rat liver tissue, human liver cancer tissue, mouse liver tissue.
Recommended antigen retrieval: heat-mediated, in TE buffer (pH 9.0); citrate buffer (pH 6.0) can be used instead.
Conditions in the example images (IHC): heat-mediated antigen retrieval in citrate buffer (pH 6).
Immunogen
Synthetic peptide from the middle region of human cytochrome p450 2C19/CYP2C19.
Reactivity Notes
The supplier lists reactivity with human, mouse and rat. UniProt places cytochrome P450 2C19 in the endoplasmic reticulum membrane and microsome membrane. The samples tested by the supplier (listed above) are a practical starting point for positive controls.
Safety
Customization & Add-ons: Can’t find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.
JinFang Hao et al. (2024) Metabolomics combined with network pharmacology reveals the protective effect of astragaloside IV on alcoholic liver disease. Phytomedicine. 10.1016/j.phymed.2024.156032
